Dosing of First Study Subjects in PK Study of VAL001

Respiratorius announces that on February 14 the first study subjects in PK study of VAL001 were dosed.

The tailored release profile of VAL001, combining immediate release and extended-release characteristics of sodium valproate, will be evaluated in the pharmacokinetic (PK) study in healthy subjects. Preliminary results of the initial part of the study are expected during quarter 1, 2022 and close out of the entire study during quarter two, 2022.

"Dosing of the first study subjects in the PK study occurred soon after site initiation and we are confident that the CRO will continue the swift patient recruitment and inclusion in the study, says CEO Johan Drott in a comment.

This disclosure contains information that Respiratorius is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 14-02-2022 10:37 CET.

Johan Drott

President Respiratorius AB

+46 709-22 41 40

johan.drott@respiratorius.com

Respiratorius AB (publ) is developing drug candidates with the goal to launch drugs for common diseases cancer, chronic obstructive pulmonary disease (COPD) and severe asthma. In addition, the project portfolio is a project for improved diagnosis of certain cardiovascular diseases.